Description: A Phase 1-2 Dose-Escalation and Expansion Study of ST101 in Patients with Advanced Unresectable and Metastatic Solid Tumors
Mechanism of action: Targets CEBP-beta, which is a transcription factor controlling multiple cellular processes (differentiation, cell survival and metabolism)
Target Patient Population: Breast (HR+), cutaneous melanoma, glioblastoma, prostate cancer
Study Design: Drug is administered IV every 3 weeks.